Losartan Potassium and Hydrochlorothiazide Tablets 50 mg/ 12.5 mg: BLK719A, BLK720A, BLK721A, BLK722A, BLK723A, BLK724A, September 2019 BLK725A, BLK726A, October 2019 BLK804A, BLK806A, January 2020 ...

The expanded recall includes an additional three lots of losartan potassium tablets USP and two lots of losartan potassium/hydrochlorothiazide tablets. The impurity is N-Methylnitrosobutyric acid.

NDC 13668-118-90, losartan potassium/hydrochlorothiazide tablets, USP 100 mg/25 mg, 90 count, batch number 4P04D007, expires on 7/31/2020.

The maker of Losartan has widened a recall of the generic blood pressure medicine for the fifth time, according to the U.S. Food and Drug Administration, which warned that some pills may be ...

More specifically, the expanded recall includes “an additional 3 lots of Losartan Potassium Tablets USP and 2 lots of Losartan Potassium/Hydrochlorothiazide Tablets, USP,” the FDA said in a ...

The voluntary recall affects Losartan potassium tablets UP and Losartan potassium-hydrochlorothiazide tablets. This recall is related to the Valsartan recall that has been expanded […] ...

The voluntary recall affects Losartan Potassium Tablets/USP and Losartan Potassium-Hydrochlorothiazide tablets.

The recall includes three additional lots of losartan potassium tablets and two lots of losartan potassium/hydrochlorothiazide tablets by Torrent Pharmaceuticals Limited.

The recall includes three additional lots of losartan potassium tablets and two lots of losartan potassium/hydrochlorothiazide tablets by Torrent Pharmaceuticals Limited.